Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned an average rating of “Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $47.5714.

Several analysts have recently commented on IMUX shares. Wolfe Research started coverage on Immunic in a report on Friday, May 22nd. They issued an “outperform” rating for the company. D. Boral Capital cut Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Guggenheim started coverage on Immunic in a report on Tuesday, March 24th. They issued a “buy” rating and a $70.00 price target for the company. Roth Mkm reissued a “buy” rating and issued a $19.00 price target on shares of Immunic in a report on Thursday, May 14th. Finally, B. Riley Financial reduced their price target on Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 22nd.

Institutional Trading of Immunic

Several hedge funds have recently modified their holdings of IMUX. OMERS ADMINISTRATION Corp purchased a new position in Immunic in the 1st quarter valued at approximately $187,000. Renaissance Technologies LLC purchased a new position in Immunic in the 1st quarter valued at approximately $1,020,000. XTX Topco Ltd purchased a new position in Immunic in the 4th quarter valued at approximately $120,000. Jane Street Group LLC increased its stake in Immunic by 46.8% in the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after purchasing an additional 91,346 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Immunic in the 3rd quarter valued at approximately $29,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Trading Down 0.3%

Shares of IMUX stock opened at $15.37 on Wednesday. The business’s 50 day moving average is $12.67 and its two-hundred day moving average is $10.12. Immunic has a twelve month low of $5.06 and a twelve month high of $15.84. The company has a market capitalization of $209.34 million, a P/E ratio of -2.75 and a beta of 1.37.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). As a group, equities analysts predict that Immunic will post -4.57 earnings per share for the current fiscal year.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.